Gilead Stands Its Ground With Harvoni: HCV Price War Less Likely
Executive Summary
Firm makes clear that pricing of Harvoni is meant to match the cost of Sovaldi plus the interferon/ribavirin therapeutic backbone. Despite stakeholder criticism, Wall Street expects Gilead’s competitors will not attempt to compete via price.